BOTHELL, Wash., Jan. 16, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced that CEO Mike Rice and CFO Roderick de Greef will be attending and presenting at the following investor conferences:

• BIO CEO & Investor Conference; February 12^th – 13^th; New York Marriott Marquis Hotel; https://www.bio.org/events/bio-ceo-investor-conference
• B Riley FBR Inaugural China Healthcare Investment & Partnering Symposium (CHIPS); March 15^th – 17^th; InterContinental Hotel Hangzhou, China; https://brcfbr.meetmax.com/sched/event_47969/~public/conference_home.html?event_id=47969

BioLife Solutions will also be attending and/or exhibiting at the following scientific conferences:

• Phacilitate Cell & Gene Therapy World 2018 conference; January 22^nd – 25^th; Hyatt Regency Miami; http://www.cellandgenetherapyworld.com
• The 2018 World Stem Cell Summit; January 22^nd – 26^th; Hyatt Regency Miami; http://www.worldstemcellsummit.com
• 4^th Annual Perinatal Stem Cell Congress; March 1^st – 2^nd; The Leonardo Museum; Salt Lake City, UT https://www.perinatalstemcells.com/2018-conference-agenda.html
• Parenteral Drug Association 2018 Annual Meeting; March 19^th – 21^st; Loews Sapphire Falls; Orlando, FL; https://www.pda.org/global-event-calendar/event-detail/2018-pda-annual-meeting
• Optimization of Cell and Gene Therapy Production, March 26^th – 27^th; The Ritz-Carlton; Washington DC; http://www.cbinet.com/conference/pc18455

About BioLife Solutions

BioLife Solutions is the leading developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues. Our proprietary HypoThermosol^® and CryoStor^® platform of solutions are highly valued in the regenerative medicine, biobanking and drug discovery markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function.

For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

Media & Investor Relations
Roderick de Greef
Chief Financial Officer
(425) 686-6002
rdegreef@biolifesolutions.com

SOURCE BioLife Solutions, Inc.